Dr. Reddy's Laboratories Ltd.

NSE: DRREDDY | BSE: 500124 | ISIN: INE089A01023 |Industry: Pharmaceuticals
|Expensive Star
4888.65 -53.30 (-1.08%)
NSE Oct 30, 2020 15:31 PM
Volume: 1.3M

ICICI Securities Limited
Dr Reddy's (DRL) has announced the settlement of its Revlimid capsules (Lenalidomide) patent litigation with Celgene [Bristol Myers Squibb (BMS)] in the US. This makes DRL the third player after Natco and Alvogen to sign a settlement agreement with the innovator for gRevlimid. Under the terms of the settlement, Celgene will provide DRL with a license to sell generic volume-limited amounts of gRevlimid capsules in the US after Natco's launch in March 2022 subject to regulatory approval. This limited volume constraint will be applicable till January 31, 2026 post which DRL will be able...
Dr. Reddy's Laboratories Ltd. is trading below it's 30 day SMA of 5095.9
More from Dr. Reddy's Laboratories Ltd.